Isocyanate asthma: respiratory symptoms due to 1,5-naphthylene di-isocyanate

M G HARRIES, P SHERWOOD BURGE, M SAMSON, A J NEWMAN TAYLOR, AND J PEPYS

From the Brompton Hospital, London, UK

ABSTRACT  Occupationaly related asthma developing in three patients due specifically to exposure to 1,5-naphthylene di-isocyanate (NDI), a hot curing agent used in manufacturing rubber, has been confirmed for the first time using bronchial provocation testing. This substance has been thought to be safer than toluene di-isocyanate (TDI) and diphenylmethane di-isocyanate (MDI) because of its relatively high melting point (120°C).

Each patient worked in the same factory and the circumstances of exposure were similar. Provocation testing was also performed with TDI in concentrations up to 0·018 parts per million (ppm) and MDI in concentrations up to 0·02 ppm, to which the patients had been exposed in the past, but no reactions were elicited. None of the patients had increased bronchial reactivity judged by histamine lability and exercise testing.

Each patient was advised to give up his job, but two of the three could not find alternative employment and remained exposed. Three-year follow-up shows that airways narrowing has persisted in those who have remained exposed.

Respiratory symptoms resulting from exposure to di-isocyanates have been recognised since the first report by Fuchs and Valade (1951) of reactions to toluene di-isocyanate (TDI). Symptoms of asthma may follow inhalation of the vapour of these compounds. The more volatile isocyanates, TDI and hexamethylene di-isocyanate (HDI), cause asthma at room temperature while solid isocyanates, diphenylmethane di-isocyanate (MDI) and 1, 5-naphthylene di-isocyanate (NDI) seldom cause problems unless they are heated (Longley, 1964; Munn, 1965; Tanser, 1973).

NDI is a solid with a melting point of 120°C. Goldblatt and Goldblatt (1956) and Munn (1965) both describe instances in which the development of asthma was thought to result from exposure to the vapour of NDI.

We describe three patients in whom asthma developed for the first time while they were working in a factory where various isocyanates were used and whose asthma was thought to be caused by the vapour of NDI, a hot curing agent used in manufacturing synthetic rubber. Using occupational-type bronchial provocation testing these symptoms were shown to result specifically from exposure to NDI vapour.

Case reports

PATIENT 1
This 46-year-old man had been engaged in 1955 as a chemist in a factory making plastic moulds using a two-part mix with either TDI, MDI, or NDI as the curing agents. He noticed a cough at work then. In 1962 he developed breathlessness and tightness in the chest especially at night and ultimately during the day. He noticed that his symptoms improved at weekends and on holiday when away from work. In 1972 the factory moved its location but undertook no change in methods of manufacture or in use of materials. His symptoms continued. He had smoked 40 cigarettes a day until 1974 and was atopic but with no past history of eczema or rhinitis. He was admitted to hospital for bronchial provocation testing in November 1975.

PATIENT 2
This 41-year-old man worked as a foreman in the same factory as the first patient at its new location and was known to have been exposed to TDI for one year in 1963. He was referred to hospital in December 1974 with a nine-month history of nasal
discharge and watering of the eyes and with a single attack of asthma after an upper respiratory infection. He was atopic and had a history of obstructive sleep apnoea. His FEV₁ and FVC were 2·5 l and 3·4 l respectively, which at that time was attributed to his smoking (40 cigarettes a day). He returned to work with recurrence of wheeze and shortness of breath, always worse first thing in the morning. His FEV₁ and FVC measured at work six hours after starting his shift showed a fall from 2·4 l and 3·2 l respectively to 1·1 l and 2·25 l. After a period off work he improved but during that time was given oral corticosteroids. In May 1975 he inhaled the fume of a mixture of NDI powder and prepolymer resin that was being heated in a fume cupboard at 135°C. Within 30 minutes he was short of breath and suffered wheeze for the next two days. He was admitted to hospital for bronchial provocation testing in June 1975.

**PATIENT 3**

This 37-year-old man worked for six years as a moulder of plastic and then as a polyurethane caster at the same factory as the first patient, both at its old location and the new one. Two years before attending hospital he was moved on the shop floor to take the place of patient 2 who had by then been shown to be sensitised to NDI. After this move he developed increasing shortness of breath and wheeze worse at night and better away from work when on holiday, but not at weekends. He had attributed his symptoms to smoking 30 cigarettes a day. He was non-atopic. He was admitted to hospital for bronchial provocation testing in April 1978.

**Bronchial provocation testing**

Since each of the patients tested was known to have been exposed to TDI, MDI, and NDI, sensitisation to any or all of these three isocyanates was possible. The exposure techniques with TDI and MDI as well as histamine and exercise testing have been described elsewhere (O'Brien et al, 1979b). Inhalation challenges were performed in a sealed cubicle measuring 6 m³. Atmospheric levels of TDI and MDI were measured with a model 700 UEI meter. NDI could not be measured in this way, and atmospheric levels were not recorded. Exposure to NDI in patients 1 and 2 was effected by inhalation of the vapour of 0·3 g of NDI crystals heated with prepolymer for a total of 60 seconds. The third patient was exposed for 60 seconds to the vapour of 500 mg of NDI crystals heated at 110°C. In each case bronchial reactivity to histamine and to exercise was also measured. Each test was conducted on a different day, and no testing was performed if the patient had suffered an asthmatic reaction on the previous day. An immediate bronchial reaction was defined as a fall in FEV₁ of 15% or more within one hour of new exposure and a non-immediate reaction as a fall in FEV₁ of 15% or more within 12 hours of exposure as compared with a control day painting with unreacted polyurethane varnish. A dual reaction comprised both components.

The first patient had an asthmatic reaction provoked by histamine nebulised for 30 seconds in a final concentration of 32 mg/ml but not to exercise. He developed no reactions to TDI in concentrations up to 0·0025 ppm or to MDI in concentrations up to 0·008 ppm but had a dual reaction provoked by NDI (fig 1).

Patients 2 and 3 showed no reactions to exercise or to histamine in increasing concentrations to 32 mg/ml or to TDI at concentrations of 0·001 ppm and 0·018 ppm respectively. The third patient was also tested with MDI at a concentration of 0·02 ppm (the threshold limit value, TLV). Both patients had non-immediate reactions provoked by exposure to NDI only (figs 2 and 3).

**Follow-up**

After evidence of sensitisation to NDI had been obtained by provocation testing, each patient was advised to avoid further exposure by giving up his job.

![Graph](http://thorax.bmj.com/)

**Fig 1 Patient 1. Bronchial provocation test by exposure to 1,5-naphthylene di-isocyanate (NDI) vapour for 60 s showing both immediate and non-immediate (dual) reactions. No reaction to toluene di-isocyanate (TDI).**
The second patient was advised to give up his job but could not find other work. He was moved to another location on the factory floor that was considered safer. His respiratory symptoms persisted, and he was treated with beclomethasone dipropionate 100 µg thrice daily. One year ago he moved to yet another part of the factory where he is still potentially exposed to the fume of NDI (table 2). He is reluctant to be followed up.

The third patient left the factory after his sensitisation had been confirmed. He is now unemployed. His symptoms are improved, and he now only requires salbutamol by inhalation occasionally (table 3).

**Discussion**

Evidence that NDI causes asthma from occupational-type bronchial provocation testing has not been reported before. Sensitivity to NDI is much less common than that to TDI, HDI, or MDI. A possible explanation for this is that it is much less widely used in industry and that it is less volatile than the other isocyanates so far mentioned. In these cases, however, NDI was being heated with a prepolymer mix to 135°C, a temperature above its melting point. Another factor of possible importance is that all the patients were heavy smokers. A cigarette tip burns at a temperature above 700°C, and contamination of the paper with NDI powder might result in inhalation of vapour. O'Brien et al (1979a) have shown that there is no correlation between smoking and sensitisation to TDI but this is volatile at room temperature, and smoking would not be expected to exert any special influences on exposure.
Sensitisation to isocyanate depends on several factors including the nature of exposure and the reactivity of the patient. The nature of exposure in all three was similar since they all worked in the same factory and patients 2 and 3 did identical jobs.

The reactivity of the patient judged by his atopic status, exercise tolerance, and histamine reactivity does not correlate well with proneness to sensitisation but O'Brien et al (1979a) have shown that those subjects highly sensitive to TDI reacting to levels less than 0.001 ppm did have increased bronchial lability to histamine. None of the subjects we tested had exercise asthma, and none of them reacted to TDI at an atmospheric level less than 0.001 ppm. Only the first patient reacted to histamine at a final concentration of 32 mg/ml with a 20% fall in FEV₁.

The mechanism of sensitisation to isocyanates is unclear, but both allergic and pharmacological mechanisms have been suggested. Karol et al (1978) have found IgE antibodies against the tolyl group of TDI suggesting that isocyanates are haptenic with the reactive portion, the NCO group, binding with serum proteins, and Zeiss et al (1979) has found specific IgE and IgG antibody to human serum albumen MDI conjugates in two patients sensitised to MDI. Butcher et al (1976) and Davies et al (1977) on the other hand have suggested that TDI acts as a beta-adrenergic receptor antagonist based on its inhibitory effect on isoprenaline-induced increase in the 3,5 cyclic AMP level in lymphocytes.

A major problem in the interpretation of asthmatic reactions to the various isocyanates is knowing to which of them the patient has been exposed in the past. Many of the industrial processes used are highly secret, and the patient may not know what chemicals are being used. Furthermore, one isocyanate may be contaminated by small quantities of another, to which some individuals may react at very low atmospheric concentrations.

Though advised to give up work immediately evidence of sensitisation had been demonstrated, only one of our patients felt able to accept this advice. The reason for this was difficulty in finding alternative employment; the patient who left is still unemployed. Follow-up in the two who remained exposed shows persistent airway narrowing, and now three months after avoidance of known exposure in one of these there is still evidence of reversible airways obstruction. Prolonged measurement of peak flow rates at home and at work in sensitised patients exposed to TDI has shown a recovery pattern longer than 70 days in some cases (Burge et al, 1979).

References


studies. Journal of Allergy and Clinical Immunology, 58, 89–100.


Requests for reprints to: Dr M G Harries, Department of Medicine, Guys Hospital, London Bridge.
Isocyanate asthma: respiratory symptoms due to 1,5-naphthylene di-isocyanate.

Thorax 1979 34: 762-766
doi: 10.1136/thx.34.6.762

Updated information and services can be found at:
http://thorax.bmj.com/content/34/6/762

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/